Modulating antibody pharmacokinetics using hydrophilic polymers

Bibliography

• Jain M, Kamal N, Batra SK. Engineering antibodies for clinical applications. Trends Biotechnol 2007;25:307-16
   PubMed Web of Science ®Google Scholar
• Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009;8:245-55
   Google Scholar
• Aggarwal S. What's fueling the biotech engine-2009-10. Nat Biotechnol 2010;28:1165-71
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-33
   PubMed Web of Science ®Google Scholar
• Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008;88:451-87
   PubMed Web of Science ®Google Scholar
• Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83-105
   PubMedGoogle Scholar
• Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60
   PubMed Web of Science ®Google Scholar
• Duncan R. Polymer conjugates for drug targeting. From inspired to inspiration!. J Drug Target 2006;14:333-5
   PubMed Web of Science ®Google Scholar
• Kopecek JP, Kopeckova T, Minko ZR, Water soluble polymers in tumor targeted delivery. J Control Release 2001;74:147-58
   PubMed Web of Science ®Google Scholar
• Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113-28
   PubMed Web of Science ®Google Scholar
• Knop K, Hoogenboom R, Fischer D, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010;49:6288-308
   PubMed Web of Science ®Google Scholar
• Gaberc-Porekar V, Zore I, Podobnik B, Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 2008;11:242-50
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S, Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103-11
   PubMed Web of Science ®Google Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002;54:531-45
   PubMed Web of Science ®Google Scholar
• Lee LS, Conover C, Shi M, Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem 1999;10:973-81
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32
   PubMed Web of Science ®Google Scholar
• Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 2005;5:601-6
   PubMed Web of Science ®Google Scholar
• Constantinou A, Chen C, Deonarain MP. Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol Lett 2010;32:609-22
   PubMed Web of Science ®Google Scholar
• Alzari PM, Lascombe MB, Poljak RJ. Three dimensional structure of antibodies. Annu Rev Immunol 1988;6:555-80
   PubMed Web of Science ®Google Scholar
• Constantinou A, Epenetos AA, Hreczuk-Hirst D, Modulation of antibody pharmacokinetics by chemical polysialylation. Bioconjug Chem 2008;19:643-50
   PubMed Web of Science ®Google Scholar
• Constantinou A, Epenetos AA, Hreczuk-Hirst D, Site-Specific Polysialylation of an Antitumor Single-Chain Fv Fragment. Bioconjug Chem 2009;20:924-31
   PubMed Web of Science ®Google Scholar
• Adams GP, Shaller CC, Chappell L, Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl Med Biol 2000;27:339-46
   PubMed Web of Science ®Google Scholar
• Popplewell AG, Tickle SP, Ladyman HM. Biological Products. Celltech Research and Development Ltd. US20070059307; 2007
   Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451-8
   PubMed Web of Science ®Google Scholar
• Sasahara K. Temperature dependence of volume changes on glycine –PEG and L-alanaine-PEG in aqueous solution. Colloid Polym Sci 1995;273:782-6
   Web of Science ®Google Scholar
• Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003;2:214-21
   PubMed Web of Science ®Google Scholar
• Fee CJ, Van Alstine JM. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconjug Chem 2004;15:1304-13
   PubMed Web of Science ®Google Scholar
• Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994;83:601-6
   PubMed Web of Science ®Google Scholar
• Yamaoka T, Tabata Y, Ikada Y. Fate of water-soluble polymers administered via different routes. J Pharm Sci 1995;84:349-54
   PubMed Web of Science ®Google Scholar
• Gursahani HJ, Riggs-Sauthier J, Pfeiffer D, Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability. J Pharm Sci 2009;98:2847-56
   PubMed Web of Science ®Google Scholar
• Cohen O, Kronman C, Chitlaru T, Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity. Biochem J 2001;357:795-802
   PubMed Web of Science ®Google Scholar
• Yang K, Basu A, Wang M, Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003;16:761-70
   PubMedGoogle Scholar
• Kitamura K, Takahashi T, Takashina K, Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun 1990;171:1387-94
   PubMed Web of Science ®Google Scholar
• Kitamura K, Takahashi T, Yamaguchi T, Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res 1991;51:4310-15
   PubMedGoogle Scholar
• Pedley RB, Boden JA, Boden R, The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 1994;70:1126-30
   PubMed Web of Science ®Google Scholar
• Delgado C, Pedley RB, Herraez A, Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 1996;73:175-82
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999;17:780-3
   PubMed Web of Science ®Google Scholar
• Yamasaki N, Matsuo A, Isobe H. Novel polyethylene glycol derivatives for modification of proteins. Agric Biol Chem 1988;52:2125-7
   Web of Science ®Google Scholar
• Koumenis IL, Shahrokh Z, Leong S, Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm 2000;198:83-95
   PubMed Web of Science ®Google Scholar
• Kubetzko S, Sarkar CA, Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005;68:1439-54
   PubMed Web of Science ®Google Scholar
• Mabry R, Rani M, Geiger R, Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun 2005;73:8362-8
   PubMed Web of Science ®Google Scholar
• Jayson GC, Parker GJ, Mullamitha S, Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005;23:973-8
   PubMed Web of Science ®Google Scholar
• Trakas N. Tzartos, SJ. Conjugation of acetylcholine receptor-protecting Fab fragments with polyethylene glycol results in a prolonged half-life in the circulation and reduced immunogenicity. J Neuroimmunol 2001;120:42-9
   PubMed Web of Science ®Google Scholar
• Leong SR, DeForge L, Presta L, Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine 2001;16:106-19
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Onda M, Nagata S, Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000;97:8548-53
   PubMed Web of Science ®Google Scholar
• Kubetzko S, Balic E, Waibel R, PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 2006;281:35186-201
   PubMed Web of Science ®Google Scholar
• Riley CJ, Engelhardt KP, Saldanha JW. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res 2009;69:1933-40
   PubMed Web of Science ®Google Scholar
• Monfardini C, Schiavon O, Caliceti O, A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 1995;6:62-9
   PubMed Web of Science ®Google Scholar
• Abuchowski A, McCoy JR, Palczuk NC, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582-6
   PubMed Web of Science ®Google Scholar
• Riley S. Business insights reports innovation in drug delivery. 2006
   Google Scholar
• Fraser-Moodie I. Business insights reports. Delivery mechanisms for large molecule drugs. 2008
   Google Scholar
• Wakefield IP, Burkly C, Garber L, CDP7657, a monovalent Fab PEG anti-CD40L antibody, inhibits immune responses in both HuSCID mice and non-human primates. Arthritis Rheum 2010;62:1245
   Google Scholar
• Ton NC, Parker GJ, Jackson A, Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res 2007;13:7113-18
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ucb.com/media-room/news-overview News archive [Accessed 5 June 11]
   Google Scholar
• Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005;5:111-24
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sweeney CJ, Papadopoulos K, Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 2011;17:363-71
   PubMed Web of Science ®Google Scholar
• Harmsen MM, van Solt CB, Fijten HP, Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol 2007;120:193-206
   PubMed Web of Science ®Google Scholar
• Devy L, Rabbani SA, Stochl M, PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia 2007;9:927-37
   PubMed Web of Science ®Google Scholar
• Fleischmann R. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. Expert Opin Biol Ther 2010;10:773-86
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348:36-41
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32
   PubMed Web of Science ®Google Scholar
• Shaunak S, Godwin A, Choi JW, Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol 2006;2:312-13
   PubMed Web of Science ®Google Scholar
• Available from: http://www.polytherics.co.uk/technologies/hipeg/ [Accessed 5 June 11]
   Google Scholar
• Available from: http://www.polytherics.co.uk/technologies/cypeg/ [Accessed 5 June 11]
   Google Scholar
• Available from: http://www.polytherics.co.uk/technologies/therapeg/ [Accessed 5 June 11]
   Google Scholar
• Humphreys DP, Heywood SP, Henry A, Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng Des Sel 2007;20:227-34
   PubMed Web of Science ®Google Scholar
• Gao W, Liu W, Christensen T, In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. Proc Natl Acad Sci USA 2010;107:16432-7
   PubMed Web of Science ®Google Scholar
• Gao W, Liu W, Mackay JA, In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics. Proc Natl Acad Sci USA 2009;106:15231-6
   PubMed Web of Science ®Google Scholar
• Available from:. http://www.ambrx.com/wt/page/site_matters [Accessed 5 June 11]
   Google Scholar
• Janas T, Janas T. Polysialic acid: structure and properties. Polysaccharides: structural diversity and functional versatility. CRC Publisher; 2004. p. 1224
   Google Scholar
• Gregoriadis G, Jain S, Papaioannou I, Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. Int J Pharm 2005;300:125-30
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, McCormack B, Wang Z, Polysialic acids: potential in drug delivery. FEBS Lett 1993;315:271-6
   PubMed Web of Science ®Google Scholar
• Fernandes AI, Gregoriadis G. Synthesis, characterization and properties of sialylated catalase. Biochim Biophys Acta 1996;1293:90-6
   PubMed Web of Science ®Google Scholar
• Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int J Pharm 2001;217:215-24
   PubMed Web of Science ®Google Scholar
• Jain S, Hreczuk-Hirst D, McCormack B, Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim Biophys Acta 2003;1622:42-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.lipoxen.com/pipeline/polyxen-product-pipeline.aspx [Accessed 5 June 11]
   Google Scholar
• Stockert R. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995;75:591-609
   PubMed Web of Science ®Google Scholar
• Besheer A, Hause G, Kressler J, Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. Biomacromolecules 2007;8:359-67
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009;23:93-109
   PubMed Web of Science ®Google Scholar
• Available from: http:/www.fresenius-kabi.com [Accessed 5 June 11]
   Google Scholar
• Duncan R, Kopeckova P, Strohalm J, Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia. Br J Cancer 1988;57:147-56
   PubMed Web of Science ®Google Scholar
• Kopecek J, Kopeckova P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010;62:122-49
   PubMed Web of Science ®Google Scholar
• Seymour LW, Flanagan PA, al-Shamkhani A, et al. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. Sel Cancer Ther 1991;7:59-73
   PubMedGoogle Scholar
• Lu ZR, Kopeckova P, Kopecek J. Polymerizable Fab' antibody fragments for targeting of anticancer drugs. Nat Biotechnol 1999;17:1101-4
   PubMed Web of Science ®Google Scholar
• Fagnani R, Hagan MS, Bartholomew R. Reduction of immunogenicity by covalent modification of murine and rabbit immunoglobulins with oxidized dextrans of low molecular weight. Cancer Res 1990;50:3638-45
   PubMed Web of Science ®Google Scholar
• Wileman TE, Foster RL, Elliott PN. Soluble asparaginase-dextran conjugates show increased circulatory persistence and lowered antigen reactivity. J Pharm Pharmacol 1986;38:264-71
   PubMed Web of Science ®Google Scholar
• Fagnani R, Halpern S, Hagan M. Altered pharmacokinetic and tumour localization properties of Fab' fragments of a murine monoclonal anti-CEA antibody by covalent modification with low molecular weight dextran. Nucl Med Commun 1995;16:362-9
   PubMed Web of Science ®Google Scholar
• Mikolajczyk SD, Meyer DL, Fagnani R, Starling. Dextran modification of a Fab'–beta-lactamase conjugate modulated by variable pretreatment of Fab' with amine-blocking reagents. Bioconjug Chem 1996;7:150-8
   PubMed Web of Science ®Google Scholar
• Richter W, Kagedal L. Preparation of dextran-protein conjugates and studies of their immunogenicity. Int Arch Allergy Appl Immunol 1972;42:885-902
   PubMedGoogle Scholar
• Kabat EA, Bezer AE. The effect of variation in molecular weight on the antigenicity of dextran in man. Arch Biochem Biophys 1958;78:306-18
   PubMed Web of Science ®Google Scholar
• Schlapschy M, Theobald I, Mack H, Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng Des Sel 2007;20:273-84
   PubMed Web of Science ®Google Scholar
• Huston JS, Levinson D, Mudgett-Hunter M, Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988;85:5879-83
   PubMed Web of Science ®Google Scholar
• Schellenberger V, Wang CW, Geething NC, A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 2009;27:1186-90
   PubMed Web of Science ®Google Scholar
• Available from:. http://www.amunix.com/content/products/overview.htm [Accessed 5 June 11]
   Google Scholar
• Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 1997;15:26-32
   PubMed Web of Science ®Google Scholar
• Wang M, Lee LS, Nepomich A, Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules. Protein Eng 1998;11:1277-83
   PubMedGoogle Scholar
• Kogelberg H, Tolner B, Sharma SK, Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. Glycobiology 2007;17:36-45
   PubMed Web of Science ®Google Scholar
• Stork R, Zettlitz KA, Muller D, N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008;283:7804-12
   Google Scholar
• Elliott S, Lorenzini T, Asher S, Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-21
   PubMed Web of Science ®Google Scholar
• Weenen C, Pena JE, Pollak SV, Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. J Clin Endocrinol Metab 2004;89:5204-12
   PubMed Web of Science ®Google Scholar
• Byrne B, Donohoe GG, O'Kennedy R. Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. Drug Discov Today 2007;12:319-26
   PubMed Web of Science ®Google Scholar
• Constantinou A. Production and study of polysialylated antibodies for improved cancer therapy. PhD thesis, Imperial College London; 2005
   Google Scholar
• Georgopoulou N, Breen KC. Overexpression of the alpha2,6 (N) sialyltransferase enzyme in human and rat neural cell lines is associated with increased expression of the polysialic acid epitope. J Neurosci Res 1999;58:641-51
   PubMed Web of Science ®Google Scholar